Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Heightened FDA Scrutiny ‘Key Risk’ For Indian Pharma: ICRA

This article was originally published in PharmAsia News

Executive Summary

US Food and Drug Administration Warning Letters are emerging as an important risk for India's pharmaceutical sector, says leading investment rating agency ICRA, with such notices climbing by 143% in calendar 2015 from the previous year.

Advertisement

Related Content

FY 2015 Drug GMP Warning Letters Hit Compounders and Foreign Sites

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

SC089397

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel